Loading...
•
Jun 30, 2021
Kala Bio Q2 2021 Earnings Report
Kala Pharmaceuticals reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
Key Takeaways
Kala Pharmaceuticals reported net product revenues of $3.1 million for the quarter ended June 30, 2021. EYSUVIS prescriptions increased by 93% compared to the first quarter of 2021. The company expanded commercial coverage for EYSUVIS to more than 96 million lives.
EYSUVIS prescriptions increased by 93% compared to the first quarter of 2021.
Commercial coverage for EYSUVIS expanded to more than 96 million lives.
Net product revenues reached $3.1 million in the second quarter of 2021.
Kala recently expanded its sales force from 91 to 105 ophthalmic sales professionals.
Forward Guidance
Kala anticipates that its cash resources as of June 30, 2021, together with anticipated revenue from EYSUVIS and INVELTYS, will enable it to fund its operations for at least two years.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...